 |
|
Nonsteroidal Anti-inflammatory Drugs and the Risk of Parkinson Disease
Honglei Chen, MD, PhD;
Shumin M. Zhang, MD, ScD;
Miguel A. Hernán, MD, DrPH;
Michael A. Schwarzschild, MD, PhD;
Walter C. Willett, MD, DrPH;
Graham A. Colditz, MD, DrPH;
Frank E. Speizer, MD;
Alberto Ascherio, MD, DrPH
Arch Neurol. 2003;60:1059-1064.
Background Nonsteroidal anti-inflammatory drugs (NSAIDs) reduce dopaminergic neuron degeneration in animal models of Parkinson disease (PD). However, no epidemiological data have been available on NSAID use and the risk of PD.
Objective To investigate prospectively whether the use of nonaspirin NSAIDs or aspirin is associated with decreased PD risk.
Design, Settings, and Participants Prospective cohorts of 44 057 men and 98 845 women free of PD, stroke, or cancer (Health Professionals Follow-up Study, 1986-2000, and Nurses' Health Study, 1980-1998).
Main Outcome Measure Newly diagnosed PD.
Results We documented 415 incident PD cases (236 men and 179 women). Participants who reported regular use of nonaspirin NSAIDs at the beginning of the study had a lower risk of PD than nonregular users during the follow-up; the pooled multivariate relative risk was 0.55 (95% confidence interval, 0.32-0.96, P = .04). Compared with nonusers, a nonsignificantly lower risk of PD was also observed among men and women who took 2 or more tablets of aspirin per day (relative risk, 0.56; 95% confidence interval, 0.26-1.21).
Conclusion These findings are consistent with the hypothesis that use of NSAIDs may delay or prevent the onset of PD.
From the Departments of Nutrition (Drs Chen, Willett, and Ascherio) and Epidemiology (Drs Zhang, Hernán, Willett, and Ascherio), Harvard School of Public Health; Division of Preventive Medicine (Dr Zhang) and Channing Laboratory (Drs Willett, Colditz, and Speizer), Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; and Department of Neurology, Massachusetts General Hospital (Dr Schwarzschild); Boston.
RELATED ARTICLE
Nonsteroidal Anti-inflammatory Drugs Protect Against Parkinson Neurodegeneration: Can an NSAID a Day Keep Parkinson Disease Away?
Mya Schiess
Arch Neurol. 2003;60(8):1043-1044.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Peripheral Inflammatory Biomarkers and Risk of Parkinson's Disease
Chen et al.
Am J Epidemiol 2008;167:90-95.
ABSTRACT
| FULL TEXT
Neuroprotective Effects of Glyceryl Nonivamide against Microglia-Like Cells and 6-Hydroxydopamine-Induced Neurotoxicity in SH-SY5Y Human Dopaminergic Neuroblastoma Cells
Lin et al.
J. Pharmacol. Exp. Ther. 2007;323:877-887.
ABSTRACT
| FULL TEXT
Prospective study of dietary pattern and risk of Parkinson disease
Gao et al.
Am. J. Clin. Nutr. 2007;86:1486-1494.
ABSTRACT
| FULL TEXT
Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease
Reynolds et al.
J. Leukoc. Biol. 2007;82:1083-1094.
ABSTRACT
| FULL TEXT
Exacerbation of Dopaminergic Terminal Damage in a Mouse Model of Parkinson's Disease by the G-Protein-Coupled Receptor Protease-Activated Receptor 1
Hamill et al.
Mol. Pharmacol. 2007;72:653-664.
ABSTRACT
| FULL TEXT
NP031112, a Thiadiazolidinone Compound, Prevents Inflammation and Neurodegeneration under Excitotoxic Conditions: Potential Therapeutic Role in Brain Disorders
Luna-Medina et al.
J. Neurosci. 2007;27:5766-5776.
ABSTRACT
| FULL TEXT
Smoking, Caffeine, and Nonsteroidal Anti-inflammatory Drugs in Families With Parkinson Disease
Hancock et al.
Arch Neurol 2007;64:576-580.
ABSTRACT
| FULL TEXT
New pharmacologic horizons in the treatment of Parkinson disease.
Bonuccelli and Del Dotto
Neurology 2006;67:S30-S38.
ABSTRACT
| FULL TEXT
Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease.
McCoy et al.
J. Neurosci. 2006;26:9365-9375.
ABSTRACT
| FULL TEXT
Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: A case-control study
Bower et al.
Neurology 2006;67:494-496.
ABSTRACT
| FULL TEXT
Etiology of Parkinson's disease
Schapira
Neurology 2006;66:S10-S23.
ABSTRACT
| FULL TEXT
The pathogenesis of cell death in Parkinson's disease
Jenner and Olanow
Neurology 2006;66:S24-S36.
ABSTRACT
| FULL TEXT
A Prospective Study of Night Shift Work, Sleep Duration, and Risk of Parkinson's Disease
Chen et al.
Am J Epidemiol 2006;163:726-730.
ABSTRACT
| FULL TEXT
Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease
Hernan et al.
Neurology 2006;66:1097-1099.
ABSTRACT
| FULL TEXT
Hormones Are Key Actors in Gene X Environment Interactions Programming the Vulnerability to Parkinson's Disease: Glia as a Common Final Pathway
MARCHETTI et al.
Ann. N. Y. Acad. Sci. 2005;1057:296-318.
ABSTRACT
| FULL TEXT
A possible role for humoral immunity in the pathogenesis of Parkinson's disease
Orr et al.
Brain 2005;128:2665-2674.
ABSTRACT
| FULL TEXT
Ablation of the Inflammatory Enzyme Myeloperoxidase Mitigates Features of Parkinson's Disease in Mice
Choi et al.
J. Neurosci. 2005;25:6594-6600.
ABSTRACT
| FULL TEXT
Physical activity and the risk of Parkinson disease
Chen et al.
Neurology 2005;64:664-669.
ABSTRACT
| FULL TEXT
Andrographolide Reduces Inflammation-Mediated Dopaminergic Neurodegeneration in Mesencephalic Neuron-Glia Cultures by Inhibiting Microglial Activation
Wang et al.
J. Pharmacol. Exp. Ther. 2004;308:975-983.
ABSTRACT
| FULL TEXT
Nonsteroidal Anti-inflammatory Drugs Protect Against Parkinson Neurodegeneration: Can an NSAID a Day Keep Parkinson Disease Away?
Schiess
Arch Neurol 2003;60:1043-1044.
FULL TEXT
|
